Quy H T W, Lan N T N, Borgdorff M W, Grosset J, Linh P D, Tung L B, van Soolingen D, Raviglione M, Cô N V, Broekmans J
Pham Ngoc Thach Tuberculosis and Lung Diseases Centre, Ho Chi Minh City, Vietnam.
Int J Tuberc Lung Dis. 2003 Jul;7(7):631-6.
To determine acquired drug resistance among failure and relapse cases after treatment of new smear-positive tuberculosis.
A cohort of 2901 patients with new smear-positive tuberculosis was enrolled in Vietnam. Sputum samples were stored at enrolment. Upon failure or relapse, another sputum sample was collected. Both were cultured and underwent drug susceptibility testing and restriction fragment length polymorphism (RFLP) typing.
Of 40 failure cases, 17 had multidrug resistance (MDR) at enrolment. At failure, 15 of the 23 (65%) patients without primary MDR had acquired MDR. Of 39 relapse cases and 143 controls, none had primary MDR.
Primary drug resistance was a strong risk factor for failure and relapse and for acquiring further resistance. As 80% of failure cases had MDR, the standard re-treatment regimen appears inadequate for failure cases in this control programme with a very high cure rate among new cases.
确定新涂阳肺结核治疗失败和复发病例中的获得性耐药情况。
在越南纳入了2901例新涂阳肺结核患者队列。入组时储存痰标本。出现治疗失败或复发时,采集另一份痰标本。两份标本均进行培养并进行药敏试验和限制性片段长度多态性(RFLP)分型。
40例治疗失败病例中,17例在入组时存在耐多药(MDR)。治疗失败时,23例无原发性MDR的患者中有15例(65%)获得了MDR。39例复发病例和143例对照中,均无原发性MDR。
原发性耐药是治疗失败和复发以及获得进一步耐药的强烈危险因素。由于80%的治疗失败病例存在MDR,在该新病例治愈率很高的防治项目中,标准复治方案对治疗失败病例似乎并不充分。